Imiquimod inhibits the growth of SGC‑7901 cells in vitro through induction of autophagy and apoptosis

Jiang,Jiong; Dong,Lei; Shi,Hai‑Tao; Guo,Xiao‑Yan; Qin,Bin; Wang,Yan; Li,Hong

doi:10.3892/mmr.2015.4524

Imiquimod inhibits the growth of SGC‑7901 cells in vitro through induction of autophagy and apoptosis

Authors:
- Jiong Jiang
- Lei Dong
- Hai‑Tao Shi
- Xiao‑Yan Guo
- Bin Qin
- Yan Wang
- Hong Li
View Affiliations

Affiliations: Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710003, P.R. China
Published online on: November 6, 2015 https://doi.org/10.3892/mmr.2015.4524
Pages: 393-397

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Imiquimod, the most prominent Toll‑like receptor 7 agonist, has direct anti‑tumor activity and can induce autophagy and apoptosis in various types of human cancer. The aim of the present study was to examine the anti‑tumor effects of imiquimod and their underlying mechanisms in SGC‑7901 cells. Imiquimod exerted an inhibitory effect on cell proliferation in a dose‑ and time‑dependent manner as indicated by an MTT assay. Imiquimod induced autophagy as well as apoptosis, while simultaneous treatment with 3‑methyladenine (3-MA), an autophagy inhibitor, decreased the toxicity of imiquimod. Furthermore, blocking of autophagy by 3‑MA exerted an inhibitory effect on imiquimod-induced apoptosis, which indicated that autophagy can function as a mechanism which, upon activation, directly leads to apoptosis and cell death of SGC‑7901 cells. The results of the present study suggested that imiquimod has potent direct activity against gastric cancer cells by inducing autophagy and apoptosis.

View Figures

View References

1	Akira S and Takeda K: Toll-like receptor signalling. Nat Rev Immunol. 4:499–511. 2004. View Article : Google Scholar : PubMed/NCBI
2	Suzuki N, Suzuki S and Yeh WC: IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol. 23:503–506. 2002. View Article : Google Scholar : PubMed/NCBI
3	Tse K and Horner AA: Update on toll-like receptor-directed therapies for human disease. Ann Rheum. 66(Suppl 3): iii77–iii80. 2007. View Article : Google Scholar
4	Miller RL, Gerster JF, Owens ML, Slade HB and Tomai MA: Imiquimod applied topically: A novel immune response modifier and new class of drug. Int J Immunopharmacol. 21:1–14. 1999. View Article : Google Scholar : PubMed/NCBI
5	Yi JY, Jung YJ, Choi SS, Hwang J and Chung E: Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2 cells. Biochem Biophys Res Commun. 386:455–458. 2009. View Article : Google Scholar : PubMed/NCBI
6	Schön MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, Gollnick H and Schön M: Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol. 122:1266–1276. 2004. View Article : Google Scholar : PubMed/NCBI
7	Huang SW, Liu KT, Chang CC, Chen YJ, Wu CY, Tsai JJ, Lu WC, Wang YT, Liu CM and Shieh JJ: Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells. Br J Dermatol. 163:310–320. 2010. View Article : Google Scholar : PubMed/NCBI
8	Rubinsztein DC, Gestwicki JE, Murphy LO and Klionsky DJ: Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 6:304–312. 2007. View Article : Google Scholar : PubMed/NCBI
9	Schönthal AH: Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer Lett. 275:163–169. 2009. View Article : Google Scholar
10	Gozuacik D and Kimchi A: Autophagy as a cell death and tumor suppressor mechanism. Oncogene. 23:2891–2906. 2004. View Article : Google Scholar : PubMed/NCBI
11	Mathew R, Karantza-Wadsworth V and White E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007. View Article : Google Scholar : PubMed/NCBI
12	Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006.PubMed/NCBI
13	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. IntJ Cancer. 127:2893–2917. 2010. View Article : Google Scholar
14	Mizushima N and Yoshimori T: How to interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007. View Article : Google Scholar : PubMed/NCBI
15	Tyring S, Conant M, Marini M, Van Der Meijden W and Washenik K: Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol. 41:810–816. 2002. View Article : Google Scholar : PubMed/NCBI
16	Han JH, Lee J, Jeon SJ, Choi ES, Cho SD, Kim BY, Kim DJ and Park JH and Park JH: In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod. Int J Oncol. 42:2087–2093. 2013.PubMed/NCBI
17	Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H and Scherr DS: Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol. 177:2347–2351. 2007. View Article : Google Scholar : PubMed/NCBI
18	Schwartz MJ, Liu H, Hwang DH, Kawamoto H and Scherr DS: Antitumor effects of an imidazoquinoline in renal cell carcinoma. Urology. 73:1156–1162. 2009. View Article : Google Scholar : PubMed/NCBI
19	Ahn MY, Kwon SM, Cheong HH, Park JH, Lee J, Min SK, Ahn SG and Yoon JH: Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J Oral Pathol Med. 41:540–546. 2012.PubMed/NCBI
20	Jiang J, Dong L, Qin B, Guo X, Li H, Shi H and Liu Y: Expression of Toll-like receptor 7 (TLR7) in gastric cancer cell lines and effects of TLR7 agonist on proliferation and apoptosis of SGC-7901 cells in vitro. J South Med Univ. 34:1606–1610. 2014.In Chinese.
21	Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature. 451:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
22	Liu D and Gao M: A hypothesis. Med Sci Monit. 19:794–796. 2013. View Article : Google Scholar : PubMed/NCBI